Precision Promise Platform Trial for Metastatic Pancreatic Cancer Precision PromiseSM

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Pancreatic Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To be eligible for this trial the following criterias must be met: 1) Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (PDAC) and eligible for treatment in the first line or second line settings *Note: prior adjuvant or neoadjuvant chemotherapy is permitted if the last dose was > 12 months prior and all the other conditions below are met. 2) Radiographically measurable disease of at least one site by computed by(CT) scan (or magnetic resonance imaging,if allergic to CT contrast media) as defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Imaging results must be obtained within the 28-day window, prior to randomization.

You may not be eligible for this study if the following are true:

  • You will not be eligible for this trial if you have the following: 1) Subjects who received a combination of two investigational agents as part of first- line therapy (novel + novel) are excluded. Subjects who received one investigational agent or one investigational agent combined with an FDA approved chemotherapy regimen in first line will be allowed to be enrolled in Precision PromiseSM for second line therapy. 2) Received any therapy within 28 days (or 5 half-lives, whichever is shorter,) prior to randomization. 3) History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.